Bayer HealthCare’s dermatology subsidiary Intendis and Kythera Biopharmaceuticals, Inc. have concluded a licensing and development agreement to develop the substance ATX-101 for use in aesthetic dermatology. ATX-101 is an injectable adipolytic agent intended for the reduction of small volumes of fat. The two companies are to collaborate closely on a Phase III study in Europe starting this year to assess the effectiveness of ATX-101 in removing localized fat deposits under the chin.
It is planned that Intendis will obtain the marketing authorizations and commercialize ATX-101 outside the United States and Canada, while Kythera retains the rights to develop and commercialize the product in North America. “As a first-in-class candidate for minimally invasive fat removal, we see ATX-101 as a strong growth opportunity and an excellent entry point into the aesthetic dermatology market,” said Marc Lafeuille, President and CEO of Intendis.